Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Accumulated Expenses (2016 - 2026)

Standard Biotools has reported Accumulated Expenses over the past 16 years, most recently at $29.8 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 1783.81% to $29.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.8 million through Dec 2025, up 1783.81% year-over-year, with the annual reading at $29.8 million for FY2025, 1783.81% up from the prior year.
  • Accumulated Expenses was $29.8 million for Q4 2025 at Standard Biotools, up from $6.3 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $29.8 million in Q4 2025 and troughed at $825000.0 in Q4 2023.
  • The 5-year median for Accumulated Expenses is $7.0 million (2022), against an average of $7.5 million.
  • The largest YoY upside for Accumulated Expenses was 1783.81% in 2025 against a maximum downside of 87.5% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $8.7 million in 2021, then crashed by 86.51% to $1.2 million in 2022, then fell by 29.49% to $825000.0 in 2023, then soared by 91.64% to $1.6 million in 2024, then skyrocketed by 1783.81% to $29.8 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Accumulated Expenses are $29.8 million (Q4 2025), $6.3 million (Q3 2025), and $10.1 million (Q2 2025).